Leah Lawrence

GU Oncology Now

Neoadjuvant radio-immunotherapy followed by radical cystectomy was a safe and feasible treatment option for patients with locally advanced bladder cancer, according to data from the RACE IT trial.Sebastian C. Schmid, of Technical University of Munich, Germany, presented the trial results at the ESMO Congress 2022.The small study included 33 patients with locally advanced urothelial bladder cancer who were eligible for radical cystectomy but unfit for or refusing neoadjuvant chemotherapy.Patients were treated with nivolumab 240 mg every 2 weeks for 4 cycles, starting at 1 week before radiotherapy of the bladder/pelvis with 50.4 Gy, followed by radical cystectomy. The primary end point was the rate of patients with completed treatment at week 15, defined at 2 or more cycles of nivolumab, 23 or more fractions of radiation therapy, and cystectomy in time until the end of week 15. Median follow-up was 11.2 months.Thirty-one of the 33 patients were eligible for the efficacy analysis. The majority of patients complete treatment at week 15 (87.1%). The median number of nivolumab cycles was four.Radiological overall response rate was 70.9%. Partial response occurred in 54.8% and complete response in 16.1% of patients.Survival data are immature. The disease-free survival rate at 12 months was 90.6%.About half of patients (54.5%) experience a treatment-related adverse event of any grade. Most treatment-related adverse events were grade 1/2. The most common were thyroid and gastrointestinal disorders and skin reactions. About one-quarter (25.8%) of patients had to discontinue nivolumab due to treatment-related adverse events.&nbsp;ReferenceESMO Congress 2022 &ndash; LBA75 &ndash; RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) &ndash; first results

Neoadjuvant Radio-Immunotherapy Safe Option for Locally Advanced Bladder Cancer

European Society for Medical Oncology Congress 2022

ESMO 2022

The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.

Radio-Immunotherapy Safe Option for Bladder Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe